

INTRODUCTION	01	> International accounting transition	92	26 Employee costs and share option plans for employees	153
AstraZeneca and our year in brief	01	> New accounting standards	92	27 Commitments and contingent liabilities	158
Financial highlights	02	> Sarbanes-Oxley Act section 404	92	28 Leases	174
Chairman's statement	04	> Results of operations – summary analysis of year to 31 December 2006	93	29 Statutory and other information	175
Chief Executive Officer's review	05	> Financial position, including cash flow and liquidity – 2006	95	30 Share capital of parent company	176
DIRECTORS' REPORT	08	REMUNERATION REPORT	98	Principal subsidiaries	177
Goals, strategy and performance measurement	09	FINANCIAL STATEMENTS	116	Independent auditors' report to the members of AstraZeneca PLC (Company)	178
Business environment	13	Preparation of the Financial Statements and Directors' responsibilities	116	Company balance sheet	179
Business organisation	17	Directors' responsibilities for, and report on, internal control over financial reporting	116	Accounting policies (Company)	180
> Board of Directors at 31 December 2007	18	Auditors' reports on the Financial Statements and on internal control over financial reporting (Sarbanes-Oxley Act section 404)	117	Notes to the Financial Statements (Company)	181
> Chief Executive Officer, delegation of authority and Senior Executive Team	20	Independent auditors' report to the members of AstraZeneca PLC (Group)	117	1 Fixed asset investments	181
Our resources, skills and capabilities	21	Consolidated income statement	118	2 Other debtors	181
> Medicines	21	Consolidated statement of recognised income and expense	118	3 Non-trade creditors	181
> Research and development	23	Consolidated balance sheet	119	4 Loans	181
> R&D governance and portfolio management	27	Consolidated cash flow statement	120	5 Reserves	182
> Development pipeline at 31 January 2008	28	Accounting policies (Group)	121	6 Reconciliation of movement in shareholders' funds	182
> Sales and marketing	31	Notes to the Financial Statements (Group)	124	7 Share capital	182
> Intellectual property	33	1 Operating profit	124	8 Commitments and contingent liabilities	183
> Supply and manufacturing	33	2 Restructuring and synergy costs	124	9 Statutory and other information	183
> People	35	3 Finance income and expense	125	Group financial record	184
> Main facilities	37	4 Taxation	125	ADDITIONAL INFORMATION	186
Corporate governance and managing risk	38	5 Earnings per \$0.25 Ordinary Share	127	Shareholder information	186
Cardiovascular (CV) medicines	50	6 Segment information	128	Risk	193
Gastrointestinal (GI) medicines	53	7 Product sales information	130	Corporate information	200
Neuroscience medicines	56	8 Property, plant and equipment	131	Cross-reference to Form 20-F	201
Oncology medicines	59	9 Goodwill	132	Glossary	202
Respiratory and Inflammation (R&I) medicines	63	10 Intangible assets	133	Cautionary statement regarding forward-looking statements	
Infection medicines	66	11 Other investments	134	The purpose of this Annual Report and Form 20-F Information is to provide information to the members of the Company. In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995 and the UK Companies Act 2006, we are providing the following cautionary statement: This Annual Report and Form 20-F Information contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of the preparation of this Annual Report and Form 20-F Information and the Company undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things, those factors identified in the section 'Risk' on pages 193 to 199 of this document. Nothing in this Annual Report and Form 20-F Information should be construed as a profit forecast.	
Other businesses	68	12 Inventories	134		
Geographical review	69	13 Trade and other receivables	135		
In the global community	73	14 Cash and cash equivalents	135		
Environmental review	75	15 Interest bearing loans and borrowings	135		
Financial review	77	16 Financial risk management objectives and policies	136		
> Measuring performance	77	17 Financial instruments	138		
> Business background and major events affecting 2007	78	18 Trade and other payables	142		
> Results of operations – summary analysis of year to 31 December 2007	79	19 Provisions for liabilities and charges	142		
> Financial position, including cash flow and liquidity	81	20 Statement of changes in equity	143		
> Acquisition of MedImmune	83	21 Reserves	144		
> Restructuring and synergy costs	84	22 Minority interests	145		
> Capitalisation and shareholder return	84	23 Dividends to shareholders	145		
> Future prospects	84	24 Acquisitions of business operations	145		
> Financial risk management policies	85				
> Critical accounting policies and estimates	86				
> Off-balance sheet transactions, contingent liabilities and commitments	90				

ASTRAZENECA IS ONE OF THE WORLD'S LEADING PHARMACEUTICAL COMPANIES WITH A BROAD RANGE OF MEDICINES DESIGNED TO FIGHT DISEASE IN IMPORTANT AREAS OF HEALTHCARE. BACKED BY STRONG SCIENCE AND WIDE-RANGING COMMERCIAL SKILLS, WE ARE COMMITTED TO SUSTAINABLE DEVELOPMENT OF OUR BUSINESS AND THE DELIVERY OF A FLOW OF NEW MEDICINES THAT BRING BENEFIT FOR PATIENTS AND CREATE ENDURING VALUE FOR OUR SHAREHOLDERS AND SOCIETY.

2007 IN BRIEF

- > Sales up 7% to \$29,559 million.
- > *Crestor* sales up 33% to \$2,796 million;
Symbicort up 22% to \$1,575 million;
Seroquel up 15% to \$4,027 million;
and *Arimidex* up 10% to \$1,730 million.
Nexium sales down 2% to \$5,216 million.
- > Our product portfolio now includes 11 medicines with annual sales of more than \$1 billion each.
- > Sales up 17% in emerging markets.
- > Operating profit (excluding restructuring and synergy costs) up 8% to \$9,060 million.
- > Cash distributions to shareholders totalled \$6,811 million (dividends \$2,641 million; share re-purchases \$4,170 million).
- > Earnings per share (excluding restructuring and synergy costs) were \$4.20, ahead of target.
- > Dividend up 9% to \$1.87 for the full year.
- > Investment in R&D increased to more than \$5 billion.
- > A record 36 new compounds were selected for development and 24 compounds progressed to first human exposure. Phase III development pipeline doubled from five to 10 projects.
- > Over 20 major externalisation deals and two significant acquisitions in the past two years.
- > Acquisition of MedImmune in June 2007 established us as a leader in biotechnology amongst our pharmaceutical peers.
- > Productivity initiatives, including restructuring programme, progressing to plan.

FINANCIAL HIGHLIGHTS

Growth rates represent underlying performance, which shows growth at constant exchange rates (CER) by excluding the effects of exchange rate movements. Underlying CER growth is calculated by retranslating the current year's performance at the previous year's exchange rates and adjusting for other exchange effects, including hedging.

SALES \$M		
		GROWTH
07	29,559	+7%
06	26,475	+11%
05	23,950	+10%

OPERATING PROFIT \$M		
		GROWTH
07 ¹	9,060	+8%
07	8,094	-4%
06	8,216	+28%
05	6,502	+39%

PROFIT BEFORE TAX \$M		
		GROWTH
07 ¹	8,949	+2%
07	7,983	-9%
06	8,543	+29%
05	6,667	+41%

EARNINGS PER ORDINARY SHARE \$		
		GROWTH
07 ¹	4.20	+7%
07	3.74	-5%
06	3.86	+34%
05	2.91	+41%

R&D INVESTMENT \$M		
		GROWTH
07 ¹	5,089	+22%
07	5,162	+24%
06	3,902	+16%
05	3,379	-4%

SG&A COSTS \$M		
		GROWTH
07 ¹	9,886	+4%
07	10,364	+9%
06	9,096	+5%
05	8,695	+4%

RETURNS TO SHAREHOLDERS – DIVIDENDS AND SHARE RE-PURCHASES \$M		
07	6,811	
06	6,367	
05	4,718	

¹ Excluding restructuring and synergy costs.

PRODUCT PERFORMANCE SUMMARY \$M

NEXIUM -2%

07	5,216
06	5,182
05	4,633

SEROQUEL +15%

07	4,027
06	3,416
05	2,761

CRESTOR +33%

07	2,796
06	2,028
05	1,268

ARIMIDEX +10%

07	1,730
06	1,508
05	1,181

SYMBICORT +22%

07	1,575
06	1,184
05	1,006

PULMICORT +10%

07	1,454
06	1,292
05	1,162

SELOKEN/TOPROL-XL -22%

07	1,438
06	1,795
05	1,735

CASODEX +6%

07	1,335
06	1,206
05	1,123

ATACAND +9%

07	1,287
06	1,110
05	974

LOSEC/PRILOSEC -20%

07	1,143
06	1,371
05	1,652

ZOLADEX +4%

07	1,104
06	1,008
05	1,004

MERREM +20%

07	773
06	604
05	505

SYNAGIS¹

07	618
----	-----

FLUMIST¹

07	53
----	----

¹ Sales of MedImmune products are consolidated in AstraZeneca accounts from 1 June 2007. As a result, there are no prior period sales included.

DIVIDEND FOR 2007

	\$	Pence	SEK	Payment date
First interim dividend	0.52	25.3	3.49	17 September 2007
Second interim dividend	1.35	67.7	8.61	17 March 2008
Total	1.87	93.0	12.10	

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.